Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 4/20 | 0.51 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.51 |
| ▸ | ROS1 | P08922 | 2/20 | 0.51 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.49 |
| ▸ | FER | P16591 | 2/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | LTK | P29376 | 1/20 | 0.48 |
| ▸ | CDK8 | P49336 | 1/20 | 0.48 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.45 |
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.45 |
| ▸ | DRD1 | P21728 | 3/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.45 |
| ▸ | HTR2A | P28223 | 3/20 | 0.45 |
| ▸ | HTR2C | P28335 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29927169 | 1.00 | CDK5 (0.51) | CDK5ACVR1LRRK2ROS1CSNK1G1 | |
| SCHEMBL4838624 | 0.83 | CSNK1G1 (0.40) | CDK5ACVR1LRRK2ROS1CSNK1G1 | |
| SCHEMBL4836569 | 0.79 | CHRM2 (0.45) | CDK5ACVR1LRRK2ROS1CSNK1G1 | |
| SCHEMBL7658523 | 0.73 | MAPT (0.47) | CDK5ACVR1LRRK2ROS1CSNK1G1 | |
| SCHEMBL5731723 | 0.73 | AHR (0.45) | CDK5ACVR1LRRK2ROS1CSNK1G1 | |
| SCHEMBL12208493 | 0.72 | DRD2 (0.61) | CHRM2CHRM4CHRM5CHRM1DRD2 | |
| SCHEMBL4613777 | 0.71 | CHRM2 (0.41) | CHRM2CHRM4CHRM5CHRM1DRD2 | |
| Dimethylamine SCHEMBL7666545 | 0.70 | MAPT (0.44) | CDK5ACVR1LRRK2ROS1CSNK1G1 | |
| SCHEMBL22076574 | 0.70 | DRD2 (0.58) | CHRM2CHRM4CHRM5CHRM1DRD2 | |
| SCHEMBL8490022 | 0.70 | CHRM1 (0.58) | CHRM2CHRM4CHRM5CHRM1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367213-A1 | IMMEDIATE RELEASE MULTILAYER TABLET | ALKERMES PHARMA IRELAND LTD (IE) | 2025-12-04 | — | — | US | disclosed |
| US-20250352554-A1 | INTRANASAL OLANZAPINE FORMULATIONS AND METHODS OF THEIR USE | NEURELIS, INC. (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250302741-A1 | INTRANASAL OLANZAPINE FORMULATIONS AND METHODS OF THEIR USE | NEURELIS, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250262221-A1 | IMMEDIATE RELEASE MULTILAYER TABLET | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2025-08-21 | — | — | US | disclosed |
| US-12390474-B2 | Immediate release multilayer tablet | ALKERMES PHARMA IRELAND LIMITED (IE) | 2025-08-19 | — | — | US | disclosed |
| US-12171868-B2 | Intranasal olanzapine formulations and methods of their use | NEURELIS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| EP-4460297-A1 | INTRANASAL OLANZAPINE FORMULATIONS AND METHODS OF THEIR USE | Neurelis, Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| CN-118871105-A | Intranasal olanzapine formulations and methods of use thereof | 纽瑞莱斯有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-11951111-B2 | Immediate release multilayer tablet | ALKERMES PHARMA IRELAND LIMITED (IE) | 2024-04-09 | — | — | US | disclosed |
| CN-117820170-A | Olanzapine genotoxic impurity and preparation method thereof | 北京哈三联科技有限责任公司 | 2024-04-05 | — | — | CN | disclosed |
| WO-2008037502-A2 | OLANZAPINE PHARMACEUTICAL COMPOSITION WITH ANHYDROUS LACTOSE | SYNTHON B.V. (NL) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008037502-A2 | OLANZAPINE PHARMACEUTICAL COMPOSITION WITH ANHYDROUS LACTOSE | SYNTHON B.V. (NL) | 2008-04-03 | — | — | WO | disclosed |
| US-20070293479-A1 | OLANZAPINE PHARMACEUTICAL COMPOSITION | OSINGA NIELS J | 2007-12-20 | — | — | US | disclosed |
| US-20070293479-A1 | OLANZAPINE PHARMACEUTICAL COMPOSITION | OSINGA NIELS J | 2007-12-20 | — | — | US | disclosed |
| US-20070293479-A1 | OLANZAPINE PHARMACEUTICAL COMPOSITION | OSINGA NIELS J | 2007-12-20 | — | — | US | disclosed |
| WO-2007134845-A2 | OLANZAPINE PHARMACEUTICAL COMPOSITION | SYNTHON B.V. (NL) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007052167-A2 | STABLE COMPOSITION FOR A PHARMACEUTICAL FORMULATION CONTAINING OLANZAPINE | ACTAVIS GROUP PTC EHF (IS) | 2007-05-10 | — | — | WO | disclosed |
| EP-1546134-B1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | LILLY CO ELI (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1546134-B1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | LILLY CO ELI (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060084643-A1 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367213-A1 | IMMEDIATE RELEASE MULTILAYER TABLET | HTR7, HTR1A, HTR3B | CDK5 1968/4885ACVR1 3902/4885LRRK2 1035/4885 |
| US-20250302741-A1 | INTRANASAL OLANZAPINE FORMULATIONS AND METHODS OF THEIR USE | FABP7, MC2R, DRD2 | CDK5 4578/4885ACVR1 4119/4885LRRK2 3764/4885 |
| US-20250352554-A1 | INTRANASAL OLANZAPINE FORMULATIONS AND METHODS OF THEIR USE | FABP7, MC2R, DRD2 | CDK5 4563/4885ACVR1 3854/4885LRRK2 3654/4885 |
| US-11951111-B2 | Immediate release multilayer tablet | HTR7, HTR1A, HTR3B | CDK5 1968/4885ACVR1 3902/4885LRRK2 1035/4885 |
| US-12390474-B2 | Immediate release multilayer tablet | HTR7, HTR1A, HTR3B | CDK5 1968/4885ACVR1 3902/4885LRRK2 1035/4885 |
| US-12171868-B2 | Intranasal olanzapine formulations and methods of their use | FABP7, MC2R, DRD2 | CDK5 4578/4885ACVR1 4119/4885LRRK2 3764/4885 |
| US-20070293479-A1 | OLANZAPINE PHARMACEUTICAL COMPOSITION | HTR2C, CACNA1D, CACNA1C | CDK5 825/4885ACVR1 3149/4885LRRK2 1144/4885 |
| US-20250262221-A1 | IMMEDIATE RELEASE MULTILAYER TABLET | HTR7, HTR1A, HTR3B | CDK5 1968/4885ACVR1 3902/4885LRRK2 1035/4885 |
| US-20060084643-A1 | Piperazine substituted aryl benzodiazepines | GABBR1, GABBR2, GABRA5 | CDK5 2137/4885ACVR1 2085/4885LRRK2 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.